SPERO THERAPEUTICS INC (SPRO) Stock Price, Quote, News and Overview
NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD
SPRO Quote, Performance and Key Statistics
2.9
0 (0%)
The current stock price of SPRO is 2.9 USD. In the past month the price increased by 9.85%. In the past year, price increased by 121.37%.
SPRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.57 | 336.94B | ||
| AMGN | AMGEN INC | 14.3 | 159.62B | ||
| GILD | GILEAD SCIENCES INC | 14.41 | 138.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 117.37B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 43.00B | ||
| ARGX | ARGENX SE - ADR | 94.8 | 33.28B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.23 | 26.43B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.02B | ||
| NTRA | NATERA INC | N/A | 22.06B | ||
| BIIB | BIOGEN INC | 8.42 | 19.52B | ||
| INSM | INSMED INC | N/A | 17.89B |
Related stock screener links
About SPRO
Company Profile
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Company Info
SPERO THERAPEUTICS INC
675 Massachusetts Ave Ste 14
Cambridge MASSACHUSETTS 02139 US
CEO: Ankit Mahadevia
Employees: 32
Phone: 18572421600
SPERO THERAPEUTICS INC / SPRO FAQ
What is the stock price of SPERO THERAPEUTICS INC today?
The current stock price of SPRO is 2.9 USD.
What is the ticker symbol for SPERO THERAPEUTICS INC stock?
The exchange symbol of SPERO THERAPEUTICS INC is SPRO and it is listed on the Nasdaq exchange.
On which exchange is SPRO stock listed?
SPRO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SPERO THERAPEUTICS INC stock?
9 analysts have analysed SPRO and the average price target is 5.1 USD. This implies a price increase of 75.86% is expected in the next year compared to the current price of 2.9. Check the SPERO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SPERO THERAPEUTICS INC worth?
SPERO THERAPEUTICS INC (SPRO) has a market capitalization of 162.14M USD. This makes SPRO a Micro Cap stock.
How many employees does SPERO THERAPEUTICS INC have?
SPERO THERAPEUTICS INC (SPRO) currently has 32 employees.
What are the support and resistance levels for SPERO THERAPEUTICS INC (SPRO) stock?
SPERO THERAPEUTICS INC (SPRO) has a support level at 2.93. Check the full technical report for a detailed analysis of SPRO support and resistance levels.
Is SPERO THERAPEUTICS INC (SPRO) expected to grow?
The Revenue of SPERO THERAPEUTICS INC (SPRO) is expected to decline by -84.86% in the next year. Check the estimates tab for more information on the SPRO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SPERO THERAPEUTICS INC (SPRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SPRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SPRO, evaluating the profitability, health, valuation and growth aspects
- SPERO THERAPEUTICS INC (SPRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SPERO THERAPEUTICS INC (SPRO) Sales and EPS estimates to see what analysts future expectations are.
- SPERO THERAPEUTICS INC (SPRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SPERO THERAPEUTICS INC (SPRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- SPERO THERAPEUTICS INC (SPRO) Stock Chart to make your own analysis
- SPERO THERAPEUTICS INC (SPRO) Latest news and press-releases to stay up to date.
Does SPERO THERAPEUTICS INC (SPRO) stock pay dividends?
SPRO does not pay a dividend.
When does SPERO THERAPEUTICS INC (SPRO) report earnings?
SPERO THERAPEUTICS INC (SPRO) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of SPERO THERAPEUTICS INC (SPRO)?
SPERO THERAPEUTICS INC (SPRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is the Short Interest ratio of SPERO THERAPEUTICS INC (SPRO) stock?
The outstanding short interest for SPERO THERAPEUTICS INC (SPRO) is 3.81% of its float. Check the ownership tab for more information on the SPRO short interest.
SPRO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SPRO. When comparing the yearly performance of all stocks, SPRO is one of the better performing stocks in the market, outperforming 99.14% of all stocks.
SPRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SPRO. The financial health of SPRO is average, but there are quite some concerns on its profitability.
SPRO Financial Highlights
Over the last trailing twelve months SPRO reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -341.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.77% | ||
| ROE | -206.31% | ||
| Debt/Equity | 0 |
SPRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to SPRO. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 35.75% and a revenue growth -84.86% for SPRO